Denali Therapeutics Inc. Stock Issued During Period, Value, Purchase of Assets
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Denali Therapeutics Inc. stock issued during period, value, purchase of assets for fiscal 2017 was $0.00, a 100.00% decline from fiscal 2016.
- Denali Therapeutics Inc. stock issued during period, value, purchase of assets for fiscal 2016 was $5.28M.
| Period end | Stock Issued During Period, Value, Purchase of Assets 3 month | Stock Issued During Period, Value, Purchase of Assets 12 month |
|---|---|---|
| 2017-12-31 | $0.00 10-K · filed 2020-02-27 | |
| 2016-12-31 | $5.28M 10-K · filed 2019-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |